Daniel J Ma1, Evanthia Galanis1, S Keith Anderson1, David Schiff1, Timothy J Kaufmann1, Patrick J Peller1, Caterina Giannini1, Paul D Brown1, Joon H Uhm1, Steven McGraw1, Kurt A Jaeckle1, Patrick J Flynn1, Keith L Ligon1, Jan C Buckner1, Jann N Sarkaria1. 1. Mayo Clinic, Rochester, Minnesota (D.J.M., E.G., T.J.K., P.J.P., C.G., P.D.B., J.H.U., J.C.B., J.N.S.); Alliance Statistics and Data Center, Mayo Clinic, Rochester, Minnesota (S.K.A.); University of Virginia, Charlottesville, Virginia (D.S.); MD Anderson Cancer Center, Houston, Texas (P.D.B.); Sioux Community Cancer Consortium, Sioux Falls, South Dakota (S.M.); Mayo Clinic, Jacksonville, Florida (K.A.J.); Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, Minnesota (P.J.F.); Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (K.L.L.); Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts (K.L.L.).
Abstract
BACKGROUND: The mammalian target of rapamycin (mTOR) functions within the phosphatidylinositol-3 kinase (PI3K)/Akt pathway as a critical modulator of cell survival. This clinical trial evaluated the combination of the mTOR inhibitor everolimus with conventional temozolomide (TMZ)-based chemoradiotherapy. METHODS: Newly diagnosed patients with glioblastoma multiforme were eligible for this single arm, phase II study. Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression. The primary endpoint was overall survival at 12 months, and secondary endpoints were toxicity and time to progression. Eleven patients were imaged with 3'-deoxy-3'-(18)F-fluorothymidine ((18)FLT)-PET/CT before and after the initial 2 doses of everolimus before initiating radiation/TMZ. Imaged patients with sufficient tumor samples also underwent immunohistochemical and focused exon sequencing analysis. RESULTS: This study accrued 100 evaluable patients. Fourteen percent of patients had grade 4 hematologic toxicities. Twelve percent had at least one grade 4 nonhematologic toxicity, and there was one treatment-related death. Overall survival at 12 months was 64% and median time to progression was 6.4 months. Of the patients who had (18)FLT-PET data, 4/9 had a partial response after 2 doses of everolimus. Focused exon sequencing demonstrated that (18)FLT-PET responders were less likely to have alterations within the PI3K/Akt/mTOR or tuberous sclerosis complex/neurofibromatosis type 1 pathway compared with nonresponders. CONCLUSION: Combining everolimus with conventional chemoradiation had moderate toxicity. (18)FLT-PET studies suggested an initial antiproliferative effect in a genetically distinct subset of tumors, but this did not translate into an appreciable survival benefit compared with historical controls treated with conventional therapy.
BACKGROUND: The mammalian target of rapamycin (mTOR) functions within the phosphatidylinositol-3 kinase (PI3K)/Akt pathway as a critical modulator of cell survival. This clinical trial evaluated the combination of the mTOR inhibitor everolimus with conventional temozolomide (TMZ)-based chemoradiotherapy. METHODS: Newly diagnosed patients with glioblastoma multiforme were eligible for this single arm, phase II study. Everolimus (70 mg/wk) was started 1 week prior to radiation and TMZ, followed by adjuvant TMZ, and continued until disease progression. The primary endpoint was overall survival at 12 months, and secondary endpoints were toxicity and time to progression. Eleven patients were imaged with 3'-deoxy-3'-(18)F-fluorothymidine ((18)FLT)-PET/CT before and after the initial 2 doses of everolimus before initiating radiation/TMZ. Imaged patients with sufficient tumor samples also underwent immunohistochemical and focused exon sequencing analysis. RESULTS: This study accrued 100 evaluable patients. Fourteen percent of patients had grade 4 hematologic toxicities. Twelve percent had at least one grade 4 nonhematologic toxicity, and there was one treatment-related death. Overall survival at 12 months was 64% and median time to progression was 6.4 months. Of the patients who had (18)FLT-PET data, 4/9 had a partial response after 2 doses of everolimus. Focused exon sequencing demonstrated that (18)FLT-PET responders were less likely to have alterations within the PI3K/Akt/mTOR or tuberous sclerosis complex/neurofibromatosis type 1 pathway compared with nonresponders. CONCLUSION: Combining everolimus with conventional chemoradiation had moderate toxicity. (18)FLT-PET studies suggested an initial antiproliferative effect in a genetically distinct subset of tumors, but this did not translate into an appreciable survival benefit compared with historical controls treated with conventional therapy.
Authors: José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Evanthia Galanis; Jan C Buckner; Matthew J Maurer; Jeffrey I Kreisberg; Karla Ballman; J Boni; Josep M Peralba; Robert B Jenkins; Shaker R Dakhil; Roscoe F Morton; Kurt A Jaeckle; Bernd W Scheithauer; Janet Dancey; Manuel Hidalgo; Daniel J Walsh Journal: J Clin Oncol Date: 2005-07-05 Impact factor: 44.544
Authors: Jann N Sarkaria; Evanthia Galanis; Wenting Wu; Patrick J Peller; Caterina Giannini; Paul D Brown; Joon H Uhm; Steven McGraw; Kurt A Jaeckle; Jan C Buckner Journal: Int J Radiat Oncol Biol Phys Date: 2010-09-23 Impact factor: 7.038
Authors: Mariella Gruber Filbin; Sukriti K Dabral; Maria F Pazyra-Murphy; Shakti Ramkissoon; Andrew L Kung; Ekaterina Pak; Jarom Chung; Matthew A Theisen; Yanping Sun; Yoko Franchetti; Yu Sun; David S Shulman; Navid Redjal; Barbara Tabak; Rameen Beroukhim; Qi Wang; Jean Zhao; Marion Dorsch; Silvia Buonamici; Keith L Ligon; Joseph F Kelleher; Rosalind A Segal Journal: Nat Med Date: 2013-09-29 Impact factor: 53.440
Authors: Nicolas Aide; Kathryn Kinross; Carleen Cullinane; Peter Roselt; Kelly Waldeck; Oliver Neels; Donna Dorow; Grant McArthur; Rodney J Hicks Journal: J Nucl Med Date: 2010-09-16 Impact factor: 10.057
Authors: Roxana S Dronca; Jacob B Allred; Domingo G Perez; Wendy K Nevala; Elizabeth A T Lieser; Michael Thompson; William J Maples; Edward T Creagan; Barbara A Pockaj; Judith S Kaur; Timothy D Moore; Benjamin T Marchello; Svetomir N Markovic Journal: Am J Clin Oncol Date: 2014-08 Impact factor: 2.339
Authors: James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli Journal: Oncotarget Date: 2012-09
Authors: Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent Journal: Neuro Oncol Date: 2015-05-01 Impact factor: 12.300
Authors: Patrick Y Wen; Mehdi Touat; Brian M Alexander; Ingo K Mellinghoff; Shakti Ramkissoon; Christine S McCluskey; Kristine Pelton; Sam Haidar; Sankha S Basu; Sarah C Gaffey; Loreal E Brown; Juan Emmanuel Martinez-Ledesma; Shaofang Wu; Jungwoo Kim; Wei Wei; Mi-Ae Park; Jason T Huse; John G Kuhn; Mikael L Rinne; Howard Colman; Nathalie Y R Agar; Antonio M Omuro; Lisa M DeAngelis; Mark R Gilbert; John F de Groot; Timothy F Cloughesy; Andrew S Chi; Thomas M Roberts; Jean J Zhao; Eudocia Q Lee; Lakshmi Nayak; James R Heath; Laura L Horky; Tracy T Batchelor; Rameen Beroukhim; Susan M Chang; Azra H Ligon; Ian F Dunn; Dimpy Koul; Geoffrey S Young; Michael D Prados; David A Reardon; W K Alfred Yung; Keith L Ligon Journal: J Clin Oncol Date: 2019-02-04 Impact factor: 44.544
Authors: Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed Journal: J Neurooncol Date: 2017-05-30 Impact factor: 4.130